Bone healing in children with osteogenesis imperfecta treated with bisphosphonates
- PMID: 15832149
- DOI: 10.1097/01.bpo.0000152940.10487.c9
Bone healing in children with osteogenesis imperfecta treated with bisphosphonates
Abstract
The long-term effects of bisphosphonate treatment in children with osteogenesis imperfecta (OI) are unknown. The aim of this study was to evaluate whether treatment with bisphosphonates interferes with the healing of fractures in a group of children with OI. Seven subjects (6 boys), aged 11.4 +/- 5.95 years, were followed for 2.5 +/- 0.84 years after the start of treatment with intravenous pamidronate (9 mg/kg/y) and/or oral alendronate (5 or 10 mg/d). Orthopaedic surgery of 24 bones was performed after 2.33 +/- 4.14 months of treatment, with 1.6 +/- 0.84 osteotomies per bone. Ambulation was started after 26.1 +/- 32.28 days. Reoperation was required in 8% of the bones due to fracture below primary fixation. Pseudoarthrosis was seen in one fracture, an osteotomy of the proximal femur (14% of the patients, as expected in an OI population). These results suggest that treatment with bisphosphonates at the administered doses does not interfere with fracture healing. Larger and longer studies are warranted.
Similar articles
-
Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.J Bone Miner Res. 2004 Nov;19(11):1779-86. doi: 10.1359/JBMR.040814. Epub 2004 Aug 23. J Bone Miner Res. 2004. PMID: 15476577
-
[Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta].Acta Chir Orthop Traumatol Cech. 2008 Jun;75(3):185-9. Acta Chir Orthop Traumatol Cech. 2008. PMID: 18601816 Slovak.
-
Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.J Bone Miner Res. 2005 Jun;20(6):977-86. doi: 10.1359/JBMR.050109. Epub 2005 Jan 18. J Bone Miner Res. 2005. PMID: 15883638 Clinical Trial.
-
Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?Ann Med. 2005;37(4):295-302. doi: 10.1080/07853890510007386. Ann Med. 2005. PMID: 16019729 Review.
-
Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.Curr Osteoporos Rep. 2017 Oct;15(5):412-418. doi: 10.1007/s11914-017-0401-0. Curr Osteoporos Rep. 2017. PMID: 28823022 Review.
Cited by
-
Osteogenesis imperfecta: an update on clinical features and therapies.Eur J Endocrinol. 2020 Oct;183(4):R95-R106. doi: 10.1530/EJE-20-0299. Eur J Endocrinol. 2020. PMID: 32621590 Free PMC article. Review.
-
Conjugated linoleic acid and glucosamine supplements may prevent bone loss in aging by regulating the RANKL/RANK/OPG pathway.Mol Biol Rep. 2023 Dec;50(12):10579-10588. doi: 10.1007/s11033-023-08839-x. Epub 2023 Nov 6. Mol Biol Rep. 2023. PMID: 37932498 Review.
-
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.Bone. 2013 Sep;56(1):204-12. doi: 10.1016/j.bone.2013.06.003. Epub 2013 Jun 14. Bone. 2013. PMID: 23774443 Free PMC article.
-
The Effects of Long-term Use of Nitrogen-containing Bisphosphonates on Fracture Healing.Cureus. 2019 Mar 25;11(3):e4307. doi: 10.7759/cureus.4307. Cureus. 2019. PMID: 31183287 Free PMC article. Review.
-
Conservative versus surgical treatment of osteogenesis imperfecta: a retrospective analysis of 29 patients.Clin Cases Miner Bone Metab. 2012 Sep;9(3):191-4. Epub 2012 Dec 20. Clin Cases Miner Bone Metab. 2012. PMID: 23289037 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical